58 results about "Nci h460" patented technology

The invention discloses a (2-pyridylaldehyde)-2,6 pyridine diacylhydrazone copper compound and a preparation method.The copper compound has high anti-cancer activity and can be used as the raw material for preparing medicine for treating human breast cancer cells (MDA) and Human large cell lung cancer (NCI-H460).Compared with platinum anti-cancer medicine commonly used at present, the copper compound has the advantages of being high in anti-cancer activity, good in lipid solubility, low in cost, simple in preparation method and the like, and provides a new means for anti-cancer medicine development.

The invention discloses dibenzonaphthyridinone compounds represented by the formula (I), which is shown in the description. In the formula (I), R1a is independently chosen from -H and -CH3O, R1b is -CH3O; when R2a is -Cl, R2b and R2c are both -H; when R2b is -Cl, R2a and R2b are both -H; when R2c is independently chosen from -F, -Cl, -Br, -CH3, -CH3O, and -CF3, R2a and R2b are both -H; and R3 is (CH2)2N(CH3)2 or (CH2)3N(CH3)2. The invention further discloses a preparation method of dibenzonaphthyridinone compounds and an application of dibenzonaphthyridinone compounds in the preparation of anti-tumor drugs. The test results show that dibenzonaphthyridinone compounds have a good effect on inhibiting the activity of cells such as human stomach cancer cell (MGC-803), human lung cancer cell (NCI-H460), human liver cancer cell (HepG-2), human liver cancer cell (BEL-7404), and the like, and thus has a good application prospect in antitumor industry.

The invention belongs to the field of biotechnology and microorganism animal cell line and particularly relates to a human big cell lung cancer cell strain with high osseous metastasis potency and a purpose of the human big cell lung cancer cell strain with high osseous metastasis potency. A human big cell lung cancer parental generation cell NCI-H460 is utilized as a source cell for screening an osseous metastasis cell, the human big cell lung cancer cell line H460BM with high osseous metastasis potency is screened, cultivated and built by screening six times inside and outside an immunodeficient mice. A preservation number is CGMCC No. 5406. The cell line can be used as an ideal cell model of directional osseous metastasis research of human lung cancer and for transformation mechanism research and anti-metastasis drug screening of human cancer.

The invention discloses a compound Chinese actinidia root Chinese medicinal composition and a preparation method and application thereof, belonging to the technical field of traditional Chinese medicines. The Chinese medicinal composition is characterized by comprising the following traditional Chinese medicines in parts by weight: 40-80 parts of Chinese actinidia root, 20-40 parts of salvia chinensis, 20-40 parts of herba scutellariae barbatae, 20-40 parts of herba oldenlandiae and 20-40 parts of giant knotweed. The compound Chinese actinidia root Chinese medicinal composition has remarkableproliferation inhibition effects on various cancer cells such as a hepatoma cell line Hep-G2, a lung cancer cell line NCI-H460, a gastric cancer cell line MGC-803, a breast cancer cell line MCF-7, a colon cancer cell line HCT-116 and the like, and can be used for reducing physical and psychological pains of a cancer patient in the chemo-treatment process and solving the problems of difficult and expensive administration.

The invention discloses an acridine-1,2,4-triazole-5-thioketone compound and a preparation method and applications of the acridine-1,2,4-triazole-5-thioketone compound. The preparation method of the compound comprises the following steps: 1) by taking an o-bromobenzoic acid and p-methoxyaniline as raw materials, taking potassium carbonate and copper powder as catalysts, and taking isopentyl alcohol or n-amyl alcohol as a solvent, reacting so as to obtain a compound 1; 2) carrying out cyclization on the compound 1 by using phosphorus oxychloride so as to obtain a compound 2; 3) after the compound 2 is dissolved by using an organic solvent, in the presence of tetrabutylammonium bromide, reacting the dissolved compound 2 with sodium sulfocyanate so as to obtain a compound 3; 4) after the compound 3 is dissolved by using an organic solvent, reacting the dissolved compound 3 with m-nitrobenzoylhydrazine so as to obtain a compound 4; and 5) reacting the compound 4 with sodium carbonate, carrying out suction filtration on a reactant, collecting filter liquor, adjusting the pH value of the filter liquor to be less than 4, separating out precipitates, and carrying out suction filtration on the precipitates. In-vitro antitumor test results show that the compound has a significant in-vitro antitumor activity to tested MGC80-3, NCI-H460 and T24.

The invention discloses application of Lycojaponicumin A in preparation of medicaments for treating lung cancer. The compound shows good anti-lung cancer activity, can be used for preparing anti-lung cancer medicaments, and belongs to the technical field of new application of medicaments. The Lycojaponicumin A can prominently inhibit non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, lung squamous cancer cells HTB-8 and human lung flat epithelial cancer cells QG-5 cultured in vitro, has a low inhibiting effect on human normal liver cells LO2 and peripheral blood lymphocytes, and shows obvious selectivity. The application of the Lycojaponicumin A in preparation of the medicaments for treating the lung cancer is made public for the first time; and because the skeleton type is completely novel, the Lycojaponicumin A has an unexpectedly strong lung cancer cell inhibiting activity.

The invention discloses an application of Lycojaponicumin C in the preparation of medicines for treating lung cancer. The compound shows good anti-lung cancer activity, can be used for the preparation of anti-lung cancer medicines and belongs to the technical field of new applications of medicines. The Lycojaponicumin C can be used for obviously inhibiting a non-small cell lung cancer cell A549, a large-cell lung cancer cell NCI-H460, a lung squamous carcinoma cell HTB-8 and a human lung epidermoid carcinoma cell QG-5 which are cultured in vitro, has a low inhibition effect on a human normal lung cell LO2 and a peripheral blood lymphocyte and shows up obvious selectivity. The application of the Lycojaponicumin C in the preparation of the medicines for treating the lung cancer is disclosed for the first time. As the skeleton type of the Lycojaponicumin C belongs to a brand-new skeleton type, the Lycojaponicumin C has unexpected strong inhibitory activity on the lung cancer cells.